Gilotrif
Chemical Name | afatinib |
Dosage Form | Tablet (oral; 20 mg, 30 mg, 40 mg) |
Drug Class | Kinase inhibitors |
System | Respiratory |
Company | Boehringer Ingelheim |
Approval Year | 2013 |
Indication
- Indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
- For the treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.